108 related articles for article (PubMed ID: 2943125)
1. [Effect of aclacinomycin B on DNA polymerase II of tumor cells].
Li ZR; Feng JB; Han R; Yin MB; Xia LJ
Zhongguo Yao Li Xue Bao; 1985 Sep; 6(3):189-92. PubMed ID: 2943125
[No Abstract] [Full Text] [Related]
2. [Effects of aclacinomycin B on biological macromolecular contents and synthesis of L1210 cells].
Li ZR; Feng JB; Liang F; Zeng SX; Han R
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1984 Jun; 6(3):174-8. PubMed ID: 6241042
[No Abstract] [Full Text] [Related]
3. [Immunomodulation by antitumor antibiotics].
Ishizuka M
Gan To Kagaku Ryoho; 1986 Mar; 13(3 Pt 2):697-700. PubMed ID: 3963840
[TBL] [Abstract][Full Text] [Related]
4. Recent studies on antibiotics and small molecular immunomodulators with potential usefulness in treating lung cancer: Part I - Antitumor antibiotics and their derivatives.
Umezawa H
Int J Clin Pharmacol Ther Toxicol; 1982 Jan; 20(1):12-8. PubMed ID: 6173340
[TBL] [Abstract][Full Text] [Related]
5. Experimental studies of new anthracyclines: aclacinomycin, THP-adriamycin and ditrisarubicins.
Umezawa K; Kunimoto S; Takeuchi T
Biomed Pharmacother; 1987; 41(5):206-13. PubMed ID: 2444279
[TBL] [Abstract][Full Text] [Related]
6. [Differentiation of human promyelocytic leukemic cells (HL-60) induced by aclacinomycin-B].
Lu Y; Han J; Liu HY; Zhong GP; Yang S; Jia TZ
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1986 Jun; 8(3):211-3. PubMed ID: 2946461
[No Abstract] [Full Text] [Related]
7. [Low molecular weight immunomodulators produced by microorganisms].
Ishizuka M
Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 2):2709-14. PubMed ID: 6508323
[TBL] [Abstract][Full Text] [Related]
8. [Effects of aclacinomycin B on nucleolar ultrastructure and function of RNA synthesis in human gastric cancer cells].
Li LH; Wang YS; Li GR
Zhongguo Yao Li Xue Bao; 1987 May; 8(3):266-71. PubMed ID: 2959026
[No Abstract] [Full Text] [Related]
9. [New anthracycline antibiotics and derivatives].
Tatsuta K
Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 2):2640-52. PubMed ID: 6594977
[TBL] [Abstract][Full Text] [Related]
10. Preparation of 4- and 6-O-methyl-aclacinomycin derivatives and their antitumor activities.
Tanaka H; Yoshioka T; Shimauchi Y; Matsushita Y; Matsuzawa Y; Oki T; Inui T
J Antibiot (Tokyo); 1981 Jul; 34(7):905-8. PubMed ID: 7287594
[No Abstract] [Full Text] [Related]
11. Aclacinomycin inhibits suppressor cells in vivo and in vitro.
Orbach-Arbouys S; Andrade-Mena CE; Berardet M; Mathe G
Behring Inst Mitt; 1984 May; (74):258-61. PubMed ID: 6236791
[TBL] [Abstract][Full Text] [Related]
12. Interaction of aclarubicin with DNA as compared with daunorubicin and doxorubicin.
Ando S; Sasada M; Uchino H; Kagawa D; Ueda T; Nakamura T
Nihon Gan Chiryo Gakkai Shi; 1986 Dec; 21(10):2343-55. PubMed ID: 3471823
[No Abstract] [Full Text] [Related]
13. Effects of aclacinomycin on cell survival and cell cycle progression of cultured mammalian cells.
Traganos F; Staiano-Coico L; Darzynkiewicz Z; Melamed MR
Cancer Res; 1981 Jul; 41(7):2728-37. PubMed ID: 6166368
[TBL] [Abstract][Full Text] [Related]
14. The effect of vivo doxorubicin (adriamycin) and aclacinomycin administration on guanylate cyclase activity in rat tissue.
Lehotay DC; Levey BA; Rogerson BJ; Levey GS
Proc Soc Exp Biol Med; 1981 Sep; 167(4):459-62. PubMed ID: 6116236
[No Abstract] [Full Text] [Related]
15. Inhibition of DNA and RNA metabolism by daunorubicin and adriamycin in L1210 mouse leukemia.
Meriwether WD; Bachur NR
Cancer Res; 1972 Jun; 32(6):1137-42. PubMed ID: 5030814
[No Abstract] [Full Text] [Related]
16. Aclarubicin (aclacinomycin A) and irradiation: evaluation using HeLa cells.
Miyamoto T; Wakabayashi M; Terasima T
Radiology; 1983 Dec; 149(3):835-9. PubMed ID: 6580675
[TBL] [Abstract][Full Text] [Related]
17. CC-1065 (NSC 298223), a novel antitumor agent that interacts strongly with double-stranded DNA.
Li LH; Swenson DH; Schpok SL; Kuentzel SL; Dayton BD; Krueger WC
Cancer Res; 1982 Mar; 42(3):999-1004. PubMed ID: 6174220
[TBL] [Abstract][Full Text] [Related]
18. [In vivo and in vitro antitumor activities of Aclacinomycin A made in China].
Yang JL; Han JX; Shen ZM; Lu LJ; Xu CH; Zhang HL; Wang DE; Xu SH
Yao Xue Xue Bao; 1988 May; 23(5):321-6. PubMed ID: 3213510
[No Abstract] [Full Text] [Related]
19. Immunosuppression as a desired pharmacological effect.
Dickneite G; Kurrle R; Seiler FR; Sedlacek HH
Behring Inst Mitt; 1984 May; (74):250-7. PubMed ID: 6236790
[TBL] [Abstract][Full Text] [Related]
20. Experimental studies on aclacinomycin.
Tone H; Nishida H; Takeuchi T; Umezawa H
Drugs Exp Clin Res; 1985; 11(1):9-15. PubMed ID: 2424701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
